You can buy or sell Mallinckrodt and other stocks, options, ETFs, and crypto commission-free!
MALLINCKRODT PUBLIC LIMITED COMPANY, also called Mallinckrodt, is a global specialty pharmaceuticals company. It develops, manufactures, markets and distributes both branded and generic specialty pharmaceutical products and medical imaging agents. Read More It operates through the Specialty Brands and Specialty Generics segments. The Specialty Brands segment includes branded medicines. The Specialty Generics segment relates to specialty generic drugs, active pharmaceutical ingredients, as well as external manufacturing. The company was founded by Gustavo Mallinckrodt, Otto Mallinckrodt and Edward Mallinckrodt in 1867 and is headquartered in Staines-Upon-Thames, the United Kingdom.
52 Week High
52 Week Low
Wall Street JournalMay 15
Opioid Makers Draw Scrutiny From Hedge Funds
Addiction experts are in wide agreement on the most effective way to help opioid addicts: Medication-assisted treatment. But most inpatient rehab facilities in the U.S. don’t offer this option. WSJ’s Jason Bellini reports on why the medication option is controversial, and in many places, hard to come by. Image: Ryno Eksteen and Thomas Williams At an investor lunch in late March, the chief executive of drugmaker Mallinckrodt PLC, one of the largest generic oxycodone producers in the U.S., said he expected t...
Yahoo FinanceMay 14
Here's Why Generic-Drug Manufacturers Were Down Monday
What happened Shares of generic-drug manufacturers were reeling Monday after the latest details of a price-fixing lawsuit were revealed. The case, which began years ago in Connecticut and Pennsylvania, now includes a stampede of attorneys general from 44 states alleging companies such as Teva Pharmaceutical (NYSE: TEVA), Mylan (NASDAQ: MYL), Lannett Company (NYSE: LCI), and Mallinckrodt (NYSE: MNK) inflated prices of common generic drugs by as much as 1,000%. According to reporting by The New York Times, ...
Yahoo FinanceMay 14
Mallinckrodt Completes Enrollment of Phase 3 Terlipressin CONFIRM Trial
-- Mallinckrodt's CONFIRM study is evaluating the efficacy and safety of terlipressin in hepatorenal syndrome type 1 -- STAINES-UPON-THAMES, United Kingdom, May 14, 2019 /PRNewswire/ -- Mallinckrodt plc (MNK), a leading global specialty pharmaceutical company, today announced that the company has achieved target enrollment of 300 participants in its Phase 3 CONFIRM clinical study to evaluate the efficacy and safety of terlipressin, an investigational agent, in adult patients with Hepatorenal Syndrome Type ...
$1.71 per share
$1.94 per share